Dopaminergic control of aldosterone secretion is independent of the renin-angiotensin system in rats.
1. In rats, intra-arterial metoclopramide, a dopamine antagonist, resulted in an elevation of plasma aldosterone at 5 min and plasma renin activity at 10 min and peak aldosterone and renin responses at 10 and 30 min respectively. 2. Pre-administration of L-dopa blunted and delayed aldosterone and renin responses to metoclopramide, indicating that metoclopramide-induced plasma aldosterone and plasma renin activity increments are mediated by a direct effect of blockade of dopamine receptors rather than other effects of this drug. 3. Pre-administration of angiotensin converting enzyme inhibitor, captopril (SQ 14 225) and the angiotensin II antagonist, saralasin, as well as bilateral nephrectomy did not significantly affect the aldosterone response to metoclopramide, Thus dopaminergic modulation of aldosterone secretion occurs independently of alterations in the renin-angiotensin system. 4. Modulating effects of dopamine on plasma aldosterone are probably mediated by direct effects as well as by interaction with other factors influencing aldosterone secretion at the adrenal zona glomerulosa.
D000450:Aldosterone / Q000097:blood / Q000378:metabolism*; D000818:Animals; D002216:Captopril / Q000494:pharmacology; D004298:Dopamine / Q000502:physiology*; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D008787:Metoclopramide / Q000494:pharmacology; D009392:Nephrectomy; D051381:Rats; D012083:Renin / Q000097:blood; D012504:Saralasin / Q000494:pharmacology; D013268:Stimulation, Chemical; D013997:Time Factors
D007980:Levodopa; D000450:Aldosterone; D002216:Captopril; D012083:Renin; D012504:Saralasin; D008787:Metoclopramide; D004298:Dopamine